Roche Holding (SWX:RO) - Aktienkurs, Nachrichten und Analyse

RO Aktienübersicht

Die Roche Holding AG ist in den Bereichen Pharmazeutika und Diagnostika in Europa, Nordamerika, Lateinamerika, Asien, Afrika, Australien und Ozeanien tätig. Mehr Details

RO grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	5/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	3/6
Dividenden	5/6

Belohnungen

66.8% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 11.15% pro Jahr

Zahlt eine zuverlässige Dividende von 3.67%

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Hat einen hohen Schuldenstand

Große einmalige Posten, die sich auf die Finanzergebnisse auswirken

Roche Holding AG Wettbewerber

Novartis

SWX:NOVN

CHF 185.4b

Dottikon ES Holding

SWX:DESN

CHF 3.3b

Cosmo Pharmaceuticals

SWX:COPN

CHF 1.0b

Merck

NYSE:MRK

US$249.2b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Roche Holding
Historische Aktienkurse
Aktueller Aktienkurs	CHF 279.20
52-Wochen-Hoch	CHF 312.00
52-Wochen-Tief	CHF 229.40
Beta	0.15
11 Monat Veränderung	-5.80%
3 Monate Veränderung	-7.73%
1 Jahr Veränderung	10.88%
33 Jahre Veränderung	-29.35%
5 Jahre Veränderung	-6.81%
Veränderung seit IPO	584.31%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	RO	CH Pharmaceuticals	CH Markt
7D	-2.7%	-0.7%	-1.1%
1Y	10.9%	12.3%	8.2%

Rendite im Vergleich zur Industrie: RO wie die Branche Swiss Pharmaceuticals , die im vergangenen Jahr eine Rendite von 12.3 erzielte.

Rendite vs. Markt: RO übertraf den Markt Swiss, der im vergangenen Jahr eine Rendite von 8.2 erzielte.

Preisvolatilität

Is RO's price volatile compared to industry and market?
RO volatility
RO Average Weekly Movement	2.3%
Pharmaceuticals Industry Average Movement	3.0%
Market Average Movement	3.2%
10% most volatile stocks in CH Market	6.9%
10% least volatile stocks in CH Market	1.6%

Stabiler Aktienkurs: RO hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: RODie wöchentliche Volatilität (2%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1896	103,605	Thomas Schinecker	www.roche.com

Die Roche Holding AG ist in den Bereichen Pharmazeutika und Diagnostika in Europa, Nordamerika, Lateinamerika, Asien, Afrika, Australien und Ozeanien tätig. Das Unternehmen bietet pharmazeutische Produkte in den therapeutischen Bereichen Anämie, Blut und solide Tumore, Dermatologie, Hämophilie, entzündliche und Autoimmunerkrankungen, neurologische Erkrankungen, Augenheilkunde, Atemwegserkrankungen und Transplantation. Das Unternehmen entwickelt auch Produkte für verschiedene therapeutische Bereiche.

Roche Holding AG's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Roche Holding im Vergleich zum Marktanteil des Unternehmens?
RO grundlegende Statistiken
Marktanteil	CHF 210.32b
Gewinn(TTM)	CHF 10.62b
Umsatz(TTM)	CHF 60.58b

19.6x

Kurs-Gewinn-Verhältnis

3.4x

Kurs-Umsatz-Verhältnis

Ist RO zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
RO Gewinn- und Verlustrechnung (TTM)
Einnahmen	CHF 60.58b
Kosten der Einnahmen	CHF 15.43b
Bruttogewinn	CHF 45.16b
Sonstige Ausgaben	CHF 34.54b
Umsatz	CHF 10.62b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	13.33
Bruttomarge	74.54%
Nettogewinnspanne	17.53%
Schulden/Eigenkapital-Verhältnis	104.8%

Wie hat sich RO auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

3.7%

Aktuelle Dividendenrendite

72%

Ausschüttungsquote

RO Aktienübersicht

Belohnungen

Risikoanalyse

Roche Holding AG Wettbewerber

SWX:NOVN

CHF 185.4b

SWX:DESN

CHF 3.3b

SWX:COPN

CHF 1.0b

NYSE:MRK

US$249.2b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Recent updates

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Aktionärsrenditen

Erträge & Einnahmen